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Alcoholic hepatitis (AH) is caused by acute inflammation of the liver in patients that consume excessive amounts of
alcohol, usually in a background of cirrhosis. AH can range from mild to severe, life threatening disease with a high
rate of short and long-term mortality. Prognostic models have been used to estimate mortality in order to identify
those that may benefit from corticosteroids or pentoxifylline. This review focuses on the different prognostic
models proposed. While limitations of the prognostic models exist, combining models may be beneficial in order
to identify responders to therapy versus non-responders.
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Alcoholic hepatitis (AH) is a syndrome due to acute in-
flammation of the liver in patients that consume excessive
amounts of alcohol [1]. Rapid onset of jaundice due to
parenchymal injury ranging from mild to severe, life-
threatening disease usually in the background of concomi-
tant cirrhosis is the hallmark presentation of AH [2].
Along with jaundice, varying symptoms and signs consist
of fever, encephalopathy, abdominal distress, ascites, vari-
ces, anemia, leukocytosis, coagulopathy, and a ratio of
serum aspartate aminotransferase (AST) to alanine ami-
notransferase (ALT) greater than 2, which rarely exceeds
300 IU per liter, are seen [3–5]. Although it is a treatable
form of alcoholic liver disease, there is a high rate of short
and long-term mortality. The overall inpatient mortality
was 6.6 %–6.8 % for acute AH and 13.6 % for chronic AH
in population-based studies [1,6]. In a Danish study, the
28-day mortality was 15 %, 84-day mortality was 24 %,
and 5-year mortality was 56 % with a further increase of
mortality in cirrhotic patients [7]. Another study from the
United Kingdom estimated a 5-year survival of 31.8 %
after index hospitalization with severe AH. Abstinence
from alcohol was the only independent predictor of long-
term survival [8].
While mild AH usually enjoys a good prognosis with
alcohol abstinence only, severe AH is associated with
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creativecommons.org/publicdomain/zero/1.0/Corticosteroids and pentoxifylline are the main pharma-
cological treatment options that have shown to improve
short-term survival, although the overall outcomes are
still poor and can cause potential adverse events [9].
Estimating prognosis and identifying those who will
need treatment is therefore extremely important. Prog-
nostic models are developed by combining two or more
items of patient data into a statistical model to poten-
tially predict clinical outcomes [10]. Non-invasive scoring
systems are important for prognosis as more invasive test-
ing such as liver biopsies can lead to increased morbidity
[11]. In this article, we review several scoring systems that
are available to assess severity and prognosis of AH.Maddrey discriminant function
The American Association for the Study of Liver Diseases
(AASLD) practice guidelines recommend that patients
suspected of having AH should have their outcome risk
stratified using the discriminant function (DF), along with
other available clinical data [2]. In a placebo-controlled
study assessing benefits of prednisolone in AH, Maddrey
et al. in 1978 first yielded the DF based on prothrombin
time (PT) and serum bilirubin concentration that identi-
fied patients with a significant risk for early mortality [12].
This was later modified in 1989 to the modified DF (or
mDF) = 4.6 (patient’s PT in seconds- control PT in sec-
onds) + total bilirubin (mg/dL) that is used today. Those
patients with mDF >32 were considered to have severe AH.
Patients with an elevated mDF and/or with encephalopathy
that received corticosteroid therapy, showed a 28-day mor-
tality of 6 % in the treatment group compared to 35 % inss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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valid index of severity of disease identifying those at 50 %
risk of death within 2 months [14]. DF has an inadequate
specificity of <40 %–62 % and a sensitivity of 67 %–100 %
for short-term (30 day) mortality [15,16]. The inaccuracy in
using DF may be accounted for the cut-off point of 32, and
had been the basis of debate on differing effectiveness of
corticosteroid treatment. Higher cut-off values have been
proposed such as cut-offs of 33, 37, 41, 42, or 44 to increase
the specificity [15–18]. However, DF scores less than 32
have also been shown to be associated with a relatively high
28-day mortality of 16.7 %. DF was shown to have a poor
diagnostic performance since it can only predict mortality
or survival 66.6 % of the time [15]. A drawback of using DF
is the variable results of PT across different laboratories.
The PT test relies on thromboplastin, a variable reagent,
making inter-laboratory results vary greatly [19]. Due to the
aforementioned limitations of DF, several other prognostic
models as listed below have therefore been developed.
Model for end-stage liver disease (MELD) score
The MELD score is calculated using bilirubin, creatinine
and international normalized ratio (INR) levels. The ob-
jective parameters were originally used to predict early
death following elective transjugular intrahepatic porto-
systemic shunts (TIPS) [20]. The use of objective and re-
producible data was subsequently shown to be a reliable
measure of short-term mortality risk in patients with
end-stage liver disease independent of complications of
portal hypertension, and is used as a disease severity
index to determine organ allocation priorities [21]. Sev-
eral studies have used the MELD score to assess disease
severity in AH. In a study by Sheth et al [18], the MELD
score had a similar performance as the DF in predicting
mortality at 30 days. The sensitivity and specificity in
predicting 30-day mortality was 86 % and 82 %, respect-
ively, for MELD scores >11 compared to 86 % and 48 %,
respectively, when DF was greater than 32. The utility of
predicting mortality using MELD score represented as
area under the curve (AUC) was 0.82 (95 % confidence
intervals (CI): 0.65–0.98), and AUC of DF was 0.86
(95 % CI: 0.70–1.00). Sheth et al. therefore suggested
that treatment for AH should be considered when
MELD score is greater than 11.
Other studies have suggested higher cut-offs for
MELD scores for predicting mortality. In a retrospective
study, Srikureja et al [22] reported that MELD score is
better than DF in predicting in-hospital mortality. An
admission MELD score ≥18 showed a sensitivity and
specificity of 85 % and 84 %, respectively, for predicting
in-hospital mortality. First week MELD score ≥20 had a
91 % sensitivity and 85 % specificity, and first week
change of MELD score ≥2 points had a 80 % sensitivity
and 75 % specificity for predicting in-hospital mortality.Dunn et al. [17], in a retrospective review of 73 patients
showed that MELD score was the only independent pre-
dictor of mortality in patients with AH. MELD was
shown to be comparable to DF in predicting 30-day and
90-day mortality. A MELD score of 21 in the study was
shown to have a sensitivity of 75 % and a specificity of
75 % to predict mortality with an estimated 90-day mor-
tality of 20 % in AH. Another study reported a 30-day and
90-day mortality rates of 5.9 % and 14.7 %, respectively in
patients with AH. MELD score >30.5 had an excellent per-
formance in predicting 30-day mortality with a sensitivity
of 100 % and specificity 94 % (AUC 0.969). Furthermore,
MELD score >19 only had a fair performance in predicting
90-day mortality with a sensitivity of 60 % and a specificity
of 60 % (AUC 0.762) [23].
In a retrospective study of 26 patients, Vaa et al [24]
compared MELD and MELD-Na in predicting 180-day
mortality in patients with AH. MELD-Na is a modified
MELD score that includes serum sodium (Na) which has
been shown to improve prediction of death in cirrhotic
patients. In the study, MELD-Na was a better predictor of
180-day mortality than MELD in patients with ascites. A
MELD score of 27 and a MELD-Na score of 28 in patients
without ascites had a sensitivity/specificity of 76.5 %/64.9 %
and 87.5 %/52.5 %, respectively. After adjustment for
MELD in AH patients without ascites, serum Na, specific-
ally hyponatremia, was not a significant predictor of mor-
tality (p = 0.83). However, in patients with ascites a MELD
score of 29 and a MELD-Na score of 34 had sensitivity/spe-
cificity of 85.7 %/31.0 % and 83.3 %/16.7 %, respectively. In
AH patients with ascites, MELD-Na had better predictabil-
ity of 180-day mortality compared to MELD (odds ratio
(OR), 2.27 for every 1-point increase in MELD-Na; 95 %
CI: 1.22–36.68; p = 0.008 versus OR, 1.37 for every 1-point
increase in MELD; 95 % CI: 1.07–2.12; p = 0.006).
Overall MELD score is a good predictor for mortality
in patients with AH. According to therapeutic algo-
rithms, an initial MELD score ≥18 and increasing serial
MELD scores over time are considered high risk for
mortality and should be used in guiding initiation of
therapeutic intervention [2].
Glasgow alcoholic hepatitis score (GAHS)
In 2005, Forrest et al. [25] used 5 variables including
age, blood urea, peripheral blood leukocyte count, serum
bilirubin, and PT, expressed as a ratio of the control
value to develop a new prognostic scoring system for
AH. Values obtained ranged from 5 to 12, separated into
those with value <9 or ≥9 points. Day 28 survival in pa-
tients with a day 1 GAHS score of <9 was 87 % com-
pared to 46 % in those with GAHS ≥9. Based on the
validation dataset, accuracy of GAHS day 1 and 7 data
had a better prediction of 28 day and 84 day outcome
than mDF. Accuracy of GAHS day 1 and 7 in predicting
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acy of 48 % and 56 %; p = 0.0016 and p = 0.0038, respect-
ively. Accuracy of GAHS day 1 and 7 in predicting 84-day
mortality was 71 % and 75 %, versus mDF accuracy of
57 % and 62 %; p = 0.0179 and p = 0.0477, respectively. In
a subsequent study in 2007 by Forrest et al. [26], patients
with a mDF ≥32 and a GAHS <9 did not benefit from
treatment with corticosteroids. However corticosteroids
therapy was associated with better survival in those with
both GAHS ≥9 and mDF ≥32 compared to no treatment
(28-day survival 78 % vs. 52 %, p = 0.002). Day 84 survival
was 59 % and 38 % (p = 0.02) in those treated and not
treated with steroids, respectively. In a recent study,
Lafferty et al. [27] showed that patients receiving cortico-
steroids with a GAHS ≥9, irrespective of mDF, had a
90-day survival of 58 % compared to 30 % in those not re-
ceiving treatment. The sensitivity and specificity of 90-day
outcome for GAHS assessment on admission was 67 %
and 78 %, respectively.
Age, serum bilirubin, INR, and serum creatinine (ABIC)
score
In 2008, Dominguez et al. [28] built a predictive score from
multivariate analysis of variables identified during admis-
sion. The resulting score: Age, serum Bilirubin, INR, and
serum Creatinine (ABIC) score = (age × 0.1) + (serum bili-
rubin × 0.08) + (serum creatinine × 0.3) + (INR × 0.8) was
validated in an independent prospective cohort. Using a
cutoff value of 6.71 and 9 the score identified patients with
AH that have a low (100 % survival), intermediate (70 %
survival), and high risk (25 % survival) of death at 90 days.
The sensitivity and specificity was 100 % and 50 % for the
cut-off of 6.71, respectively, and 70 % and 33 %, respect-
ively, for a cut-off of 9. In a retrospective study evaluating
9 different scoring systems, the sensitivity and specificity of
the ABIC score for 30-day mortality were 100 % and 20 %,
respectively, for a cut-off of 6.71, and 60 % and 80 %, re-
spectively, for a cut-off of 9. A higher ABIC cut-off of 9.5
compared to original cut-off of 9 resulted in an increased
specificity of 90 % vs. 80 % and 95 % vs. 84 % for a 30- and
90-day outcome respectively [16]. When comparing the
90-day mortality predictive accuracy of the ABIC score
with MELD, mDF, and GAHS, the ABIC score was the best
independent predictor of 90-day mortality (hazard ratio
(HR) 2.78, 95 % CI 1.90–4.09, p = 0.0001). The ABIC score
was also assessed to determine 1-year mortality, which
could be used for liver transplantation assignment. The
ABIC score was the only independent predictor of
1-year mortality (HR: 2.49, 95 % CI 1.77–3.52,
p = 0.0001), when compared to other prognostic
models. Analysis of the subgroup of patients treated
with steroids showed that the greatest response was
in the group with intermediate ABIC score (between
6.71–8.99) compared to those with either low ABIC(<6.71) or high ABIC scores (>9). In patients treated
with steroids, the ABIC score at 7 days has a better
accuracy than the Lille model in predicting mortality
at 6 months [28].
Lille model
In 2007, Louvet et al. [29] generated a prognostic model,
the Lille model, to identify “non-responders” to cortico-
steroid therapy in patients with severe AH. The model
combined six objective variables (age, renal insufficiency,
albumin, PT, bilirubin, and evolution of bilirubin at day 7)
which were highly predictive of death at 6 months in pa-
tients treated with corticosteroids (p < 0.000001). The Lille
formula is available online at http://www.lillemodel.com
or see formula in Table 1. A cut-off value of 0.45 was de-
termined to be the best identifier of patients at high risk
of death, with a sensitivity and specificity of 81 % and
76 %, respectively in the validation cohort, and 76 % and
85 %, respectively on overall patients. Patients with a Lille
score ≥0.45 had a significant decrease in 6-month survival
compared to patients with a Lille score <0.45 (25 % versus
85 %; p < 0.0001). Thus, 40 % of patients receiving steroids
can be identified to have a poor prognosis using the Lille
model. Patients receiving corticosteroids after 7 days with
a score ≥0.45 may be futile and alternative treatments
should be considered. In a prospective study regarding in-
fection in AH patients, only the Lille model (OR, 11.14;
95 % CI: 3.2–39.2, p = 0.0002) independently predicted in-
fection upon steroids use in multivariate analysis. Re-
sponders (Lille model <0.45) to steroids that developed
infection had lower survival compared to responders
that did not develop infection: 51 % vs 94 %, respect-
ively (p = 0.000001). Non-responders (Lille model ≥0.45)
that developed infection had similar survival to non-
responders that did not develop infection: 42 % vs 52 %,
respectively (p = 0.5). Thus adjuvant antibiotic therapy to
corticosteroids in the setting of severe AH may improve
survival mainly in responders [30].
Beclere model
The Beclere model was initially formulated by Poynard
et al. [31] in 1994 to determine survival in alcoholic cir-
rhosis. The final model has four variables: age, encephal-
opathy, serum bilirubin, and serum albumin to obtain a
risk score (R) for each patient using the formula
R = (0.0484 × [Age in Years] + 0.469 × [encephalopathy] +
0.537 × Loge [Bilirubin in μmol/L] - 0.052 × [Albumin
in g/L]. This model was then used by Mathurin et al. [32]
as a simulated prognostic model for a control group in a
study aimed to examine prognostic factors and long-term
survival in AH patients receiving corticosteroids. There
was no difference in 1 and 2 year survival in the observed
placebo-randomized group and the simulated control
group using the Beclere model. In a multivariate analysis,
Table 1 Prognostic scoring formulas to determine severity of acute alcoholic hepatitis
Scoring system Formula Severe Disease
mDF 4.6 (patient’s PT in seconds- control PT in seconds) + total bilirubin (mg/dL) ≥32
CTP 1 2 3
Bilirubin <2 mg/dL 2–3 mg/dL >3 mg/dL Class A 5–6 points
Albumin >3.5 g/dL 2.8–3.5 g/dL <2.8 g/dL Class B 7–9 points
INR <1.7 1.7–2.2 >2.2 Class C 10–15 points
Ascites None Mild Severe
Encephalopathy None Grade I-II Grade III-IV
MELD MELD Score = 0.957 x Loge (creatinine mg/dL) + 0.378 x Loge (bilirubin mg/dL)
+ 1.120 x Loge (INR) 0.6431* 10 (if hemodialysis, value for Creatinine is
automatically set to 4.0)
MELD≥ 21
MELD score = 3.8*loge (total bilirubin, mg/dL) + 11.2*loge (INR) + 9.6*loge
(creatinine, mg/dL)
MELD score = 9.57 x loge (Cr mg/dL) + 3.78 x loge (bili mg/dL) + 11.20 x loge
(INR) + 6.43
MELD-Na MELD-Na score = MELD Score - Na - 0.025*MELD* (140-Na) + 140
GAHS 1 2 3 ≥9
Age <50 ≥50 -
WBC (109/l) <15 ≥15 -
Urea (mmol/l) <5 ≥5 -
PT ratio <1.5 1.5–2.0 >2.0
Bilirubin (μmol/l) <125 125 - 250 >250
Lille Score Lille Score = 3.19–0.101 * (age in years) + 0.147 * (albumin day 0 in g/L) + 0.0165 *
(evolution in bilirubin level in μM) - (0.206 * renal insufficiency) - 0.0065 * (bilirubin
day 0 in μM) - 0.0096 * (INR or prothrombin time in seconds).
≥0.45




Stage of fibrosis Mild (0–3)
No fibrosis or portal fibrosis 0 Moderate (4–5)
Expansive fibrosis 0 Severe (6–9)




Canalicular or ductular 1







mDF modified Discriminant Function, CTP Child Turcotte Pugh, MELD Model for End-stage Liver Disease, GAHS Glasgow Alcoholic Hepatitis Score, ABIC Age serum
Bilirubin INR and serum Creatinine, AHHS Alcoholic Hepatitis Histologic Score
Rahimi and Pan Biomarker Research  (2015) 3:20 Page 4 of 8the corticosteroid effect (p < 0.02) and the Beclere model
risk score (p = 0.0003) had independent prognostic value
for survival. Survival was significantly better in the treatedgroups compared to the non-treated groups. The prednis-
olone - randomized group had 69 % survival (95 % CI:
57 %–81 %) and 71 % (95 % CI: 55 %–87 %) in the
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CI: 23 %–59 %; p = 0.01) in the placebo-randomized
group and 50 % (95 % CI: 37 %–63 %; p = 0.05) in
the simulated control group. However, subsequent
studies in AH patients did not further use this model
for prognostic scoring.
Alcoholic hepatitis histologic score (AHHS)
The need for liver biopsy is controversial in diagnosing
alcoholic hepatitis patients as the presence of ascites and
coagulopathy may require a transjugular approach, which
may not be readily available [33]. Altamirano et al. [34] de-
veloped a histologic scoring system based on liver biopsy
findings to predict short-term (90-day) mortality in AH
patients. The AHHS was initially developed from 121 pa-
tients admitted to a single center in Spain, and subse-
quently tested and validated in another set of 205 patients
from 5 academic centers in the United States and Europe.
After multivariate analysis, four independent histologic fea-
tures were combined in the final score: fibrosis stage (0–3)
which was separated as bridging fibrosis or cirrhosis giving
a score of +3 versus a score of 0 for absence of these fea-
tures; bilirubinostasis (0–2) was divided into a score of 0
for absence or hepatocellular only, +1 for canalicular or
ductular, and +2 for canalicular or ductular plus hepatocel-
lular; polymorphonuclear (PMN) infiltration (0–2) was de-
scribed as “mild” PMN (score +2) when usually <15 PMN
per focus were found around a hepatocyte and “marked”
PMNs were easily recognized at low magnification and
many PMNs found around damaged hepatocytes (with bal-
looning or Mallory–Denk bodies); and megamitochondria
(0–2) where none seen was +2, and seen was 0, for a total
of 9 points. Marked PMN infiltration and megamitochon-
dria were independently associated with a favorable out-
come. AHHS cut-off score categorized patients as low 0–3
(97 % survival), intermediate 4–5 (81 % survival), and high
risk 6–9 (49 % survival) of death. When combing
the AHHS with analytical scoring systems, the AHHS was
able to refine the prognostic stratification of those with a
MELD score <21 (low risk group). In patients with a
MELD score <21 (low risk group) the AHHS was able to
define 2 subgroups with different 90-day survival using a
cut-off of 5 points (94 % vs 72 %; p = 0.001). The differ-
ences in the MELD with an AHHS <5 points and those
with an AHHS ≥5 points (16 ± 8 vs 23 ± 9 points of MELD,
respectively; p < 0.0001) suggest that analytic parameters in
the MELD score, such as bilirubin, are reflected in severity
of histologic abnormalities. This would, therefore, modify
stratification of severity from a low to high risk group, and
change treatment management in these patients.
Child–Turcotte–Pugh (CTP) score
The CTP is based on 5 variables including ascites, en-
cephalopathy, serum bilirubin, albumin and PT, whichthe latter was modified in 1973 by Pugh et al. from the
original use of nutritional status in the Child-Turcotte
criteria. Each variable has a score of 1 to 3, and patients
are classified as class A (best), B (moderate), or C (worse)
to determine prognosis, originally for cirrhotic patients
undergoing surgery [35,36]. The limitations to the scoring
system include subjectivity in ascites and encephalopathy
grading, variable PT results, and a “ceiling” and “floor”
effect for arbitrary cut-off points with bilirubin and albu-
min, respectively [37]. The use of CTP score in AH is not
widely used. In 2004, Said et al [38] reported that CTP
compared to the MELD score had similar predictive abil-
ities for 3- and 6-month mortality in AH patients, with a
c-statistics of 0.85 (0.75–0.95) and 0.81 (0.70–0.92), re-
spectively. Srikureja et al. [22] retrospectively compared
MELD, CTP, and DF scores as predictive models to assess
in-hospital mortality in AH patients. CTP score was inde-
pendently associated with mortality on admission with
an AUC of 0.87 (95 % CI: 0.81–0.94). However, this was
lost with the first week change in CTP score (AUC 0.57;
95 % CI: 0.43–0.70) compared to first week change in
MELD score (AUC 0.85; 95 % CI: 0.76–0.94; p = 0.0004).
TMA and pentane (TAP) score
A recent study by Hanouneh et al. [39] identified novel
breath biomarkers in patients with AH. Six compounds
including 2-propanol, acetaldehyde, acetone, ethanol, pent-
ane, and trimethylamine (TMA) were initially shown to be
increased in patients with liver disease compared with
healthy control subjects. TMA, acetone and pentane were
significantly higher in AH compared to those with acute
decompensation or control subjects (for all, p < 0.001).
After accounting for MELD score only the associations
between TMA and pentane (TAP) to AH remained sig-
nificant (TMA, p < 0.001; pentane, p = 0.004). Combining
pentane and TMA levels in the breath was found to
have an excellent prediction accuracy to diagnose AH
(AUC 0.92). A model, named the TAP score, was then de-
veloped using the logistic regression (lr) function of the two
variables (lr = −3.71 + [0.34*TMA] - [0.087*pentane]), and
the following derived formula, TAP score = 100 × (exp [lr]/
1 + exp [lr] was used. TAP scores of ≥36 identified patients
with AH with 90 % sensitivity and 80 % specificity. There
correlation of the so called breathprint and severity of liver
disease was only moderate as presented by MELD score
(r = 0.38; 95 % CI, 0.07–0.69; p = 0.18). Larger studies are
needed to further validate these results, as only a small
group of 40 patients with AH were assessed.
Combining static and dynamic models
Louvet et al. [40] evaluated the prognostic value of com-
bining static models for AH, such as mDF, MELD score,
and ABIC score with dynamic models, such as the Lille
score. This joint effect model was able to predict outcome
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either the static or dynamic models alone (p < 0.01). The
MELD+ Lille combination model predicted survival better
than the mDF + Lille or ABIC + Lille models. Using the
joint effect model of MELD+ Lille score, a hypothetical
patient with a MELD score of 21 and Lille score at 0.45 had
a 15.3 % and 23.7 % mortality rate at 2 and 6 months, re-
spectively. The overall predicted mortality at 6 months
in the MELD + Lille model with a MELD score of
15–45 was between 8.5 %–49.7 % in a complete re-
sponder (Lille score, 0.16), and from 16.4 %–75.2 %
in a non-responder (Lille score, 0.45). The use of the
joint effect models has a better prediction of mortal-
ity in AH patients. This models can also identify high
risk of death in patients previously classified as re-
sponders, and intermediate risk of death in previous
classified non-responders.
Further indicators of prognosis in alcoholic hepatitis
Acute kidney Injury (AKI)
AKI, as per the AKIN (Acute Kidney Injury Network)
criteria, is defined as an abrupt reduction (within 48 h)
in kidney function that results in an absolute increase of
at least 0.3 mg/dL (or a 50 % increase) in serum levels of
creatinine from baseline [41]. In a retrospective study by
Altamirano et al [42], AKI was shown to markedly influ-
ence 90 day mortality in patients with AH versus with-
out AH (65 % vs. 7 %, p < 0.0001). The most accurate
predictors of AKI were the presence of systemic in-
flammatory response syndrome, serum bilirubin (espe-
cially >16 mg/dL), and elevated INR >1.7 in patients
with AH.
Change in bilirubin
Similar to the Lille score, early change in bilirubin levels
(ECBL), defined as bilirubin level at 7 days lower than
bilirubin level on the first day of treatment of steroids
was shown to be an important prognostic factor in AH
patients. Mathurin et al [43] reported that 95 % of pa-
tients with ECBL continued to have improved liver func-
tion during treatment. Six-month survival in patients with
ECBL was 82.8 ± 3.3 % versus 23 ± 5.8 % (p < 0.0001) in the
non-ECBL group. Another study by Morris and Forrest
[44] identified steroid responders, defined as a 25 % fall in
serum bilirubin after 6–9 days of treatment had a better
survival than non-responders. Non-responders were found
to have 28-day and 56-day mortality of 36.8 % and 57.9 %,
respectively, versus responders with 0 % (p = 0.0148) and
11.1 % (p = 0.0084), respectively. The above studies, there-
fore, suggest stopping steroids in non-responders.
Gastrointestinal (GI) bleed
In a recent study, Rudler et al. [45] compared the
mortality risk in AH patients who had concomitantGI bleeding (AH-GIB+) with AH patients without GI
bleeding (AH-GIB-). There was no difference in 1, 3, and
6-month probability of survival in AH-GIB+ versus AH-
GIB- groups (87.9 ± 4 % vs 84.1 ± 5 %, p = 0.56; 79.2 ± 5 %
vs 71.1 ± 7 %, p = 0.24; and 73.9 ± 6 % vs 69.9 ± 7 %,
p = 0.49, respectively). There was also no difference in re-
sponse to therapy between the two groups as well.Protein-Calorie malnutrition
Malnutrition, to some degree is found in every AH pa-
tient whether they do or do not have concomitant cir-
rhosis [46]. Mendenhall et al. [47] found that the
severity of protein energy malnutrition (PEM) correlated
with prognosis of AH patients. A moderate PEM of
60 %–79 % of normal was associated with a 29 %
6-month mortality, and severe malnutrition (PEM score
<60 %) correlated with a 45 % mortality in 6 months.
Patients with moderate malnutrition and adequate
caloric intake (>2,500 kcal/day) that were given oxan-
drolone (an anabolic steroid) had a reduced 6-month
mortality of 4 % versus 28 % in the placebo group
(p = 0.002). These findings were not seen in cases of
severe malnutrition [48]. In a randomized control trial,
AH patients received either prednisone or total enteral nu-
trition (TEN) of 2,000 kcal/day for 28 days [49]. Short term
(28-day period) mortality was 25 % and 31 % in the steroid
group and TEN group, respectively. One-year survival
probability was 39 % with steroids and 62 % with TEN.
Thus there may be a synergistic effect in using steroid and
TEN in AH treatment. In a meta-analysis, Antar et al. [50]
pooled 7 randomized control trials that compared nutri-
tional supplementation plus a normal hospital diet versus
diet alone. There was no statistical difference in mortality
between the two groups (OR, 0.80; 95 % CI: 0.42–1.52),
although there was a trend toward survival benefit with
supplemental nutrition and significant improvement in
encephalopathy (OR, 0.24; 95 % CI: 0.06–0.93). Thus nutri-
tional supplement is still regarded as beneficial.Conclusion
The available scoring systems are useful in both prog-
nostic stratification and selection of candidates for ap-
propriate therapy. Limitations of the scoring systems
include differing cut-offs to meet the best accuracy, clin-
ical and laboratory parameters that may differ, and that
one scoring system may be insufficient to determine
some patients with severe AH. Combining more than
one scoring system, e.g. DF and Lille score, MELD and
AHHS, or static and dynamic models may better define
severe AH with greater accuracy. Furthermore, deter-
mining responders versus non-responders to therapy is
important to avoid untoward adverse events associated
with treatment.
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